Phase II Clinical Trial of Gefitinib for the Treatment of Chemonaïve Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status

BACKGROUND: Patients with advanced non-small cell lung cancer (NSCLC) have no curative treatment options; therefore, improving their quality of life (QOL) is an important goal. Gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, is a safe oral agent that may be of benefit to a specific...

Descripción completa

Detalles Bibliográficos
Autores principales: Karim, Nagla Abdel, Musaad, Salma, Zarzour, Ahmad, Patil, Sadanand, Jazieh, Abdul Rahman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245085/
https://www.ncbi.nlm.nih.gov/pubmed/25520566
http://dx.doi.org/10.4137/CMO.S15172

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245085/
https://www.ncbi.nlm.nih.gov/pubmed/25520566
http://dx.doi.org/10.4137/CMO.S15172

Ejemplares similares